Bone in heart failure

Goran Loncar1,2,3*, Natasa Cvetinovic4, Mitja Lainscak5,6, Andjelka Isakovic2 & Stephan von Haehling3,7*

1Institute for Cardiovascular Diseases Dedinje, Belgrade, Serbia; 2Faculty of Medicine, University of Belgrade, Belgrade, Serbia; 3Department of Cardiology and Pneumology, University Medical Center Goettingen, Georg-August University, Goettingen, Germany; 4Department of Cardiology, University Clinical Hospital Center ‘Dr. Dragica Misovic-Dedinje’, Belgrade, Serbia; 5Department of Internal Medicine, General Hospital Murska Sobota, Murska Sobota, Slovenia; 6Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia; 7DZHK (German Centre for Cardiovascular Research), partner site Goettingen, Goettingen, Germany

Abstract

There is an increasing interest in osteoporosis and reduced bone mineral density affecting not only post-menopausal women but also men, particularly with coexisting chronic diseases. Bone status in patients with stable chronic heart failure (HF) has been rarely studied so far. HF and osteoporosis are highly prevalent aging-related syndromes that exact a huge impact on society. Both disorders are common causes of loss of function and independence, and of prolonged hospitalizations, presenting a heavy burden on the health care system. The most devastating complication of osteoporosis is hip fracture, which is associated with high mortality risk and among those who survive, leads to a loss of function and independence often necessitating admission to long-term care. Current HF guidelines do not suggest screening methods or patient education in terms of osteoporosis or osteoporotic fracture. This review may serve as a solid base to discuss the need for bone health evaluation in HF patients.

Keywords Heart failure; Osteoporosis; Fractures; Bone mineral density; Markers of bone metabolism

Received: 28 April 2019; Revised: 10 October 2019; Accepted: 17 October 2019
*Correspondence to: Stephan von Haehling, Department of Cardiology and Pneumology, University of Goettingen Medical Center, Robert-Koch-Strasse 40, 37075 Goettingen, Germany. Phone: +49 551 3920911; Email: stephan.von.haehling@web.de
Goran Loncar, Institute for Cardiovascular Diseases Dedinje, Heroja Milana Teplica 1, 11 040 Belgrade, Serbia. Phone: +381 64 145 50 13. Email: loncar_goran@yahoo.com

Heart failure

Heart failure (HF) is a major public health problem affecting millions of patients worldwide. The overall prevalence of HF is increasing, because of the aging of the population, the success in prolonging survival in patients suffering coronary events, and the success in postponing coronary events by effective prevention in those at high risk or those who have already survived a first event. The prevalence of HF is approximately 1–2% of the adult population in developed countries, rising to ≥10% among people over 70 years of age.1 The outcome of patients with HF is poor. The most recent European data demonstrate that 12 month all-cause mortality rates for acute HF and stable/ambulatory HF patients were 24% and 6%, respectively.2 In Europe, there is an increasing burden of hospitalizations due to HF.3–5 Indeed, HF is a clinical syndrome associated with diverse metabolic disturbances, many of which may adversely influence musculoskeletal and fat metabolism and provoke weight loss, that is, exaggerated loss of all body compartments (bone, skeletal muscle, and fat tissue) that may finally lead to cachexia.6–8

Heart failure and body wasting

The phenomenon of involuntary weight loss in chronic disease has been known for centuries.9 Cachexia in HF can be diagnosed and defined as involuntary non-oedematous weight loss ≥6% of total body weight within the previous 6–12 months10,11; however, several definitions have been used in clinical studies. Substantial weight loss is a strong indicator of imminent death in the course of the disease.12,13 It is also assumed that weight loss is not the cause of death but a strong predictor of poor prognosis. In addition, cachexia in
Osteoporosis and risk for heart failure

Disorders of bone metabolism, among which osteoporosis is the most prominent, are characteristics of physiological aging and commonly coexist with chronic disease, having adverse influence on quality of life. In parallel, osteoporosis has been suggested as an independent risk factor for cardiovascular disease. Low bone mineral density (BMD) is a risk factor for increased mortality in later life, especially from cardiovascular disease. Common underlying biological processes might contribute to vascular calcification and bone demineralization. Additionally, low BMD predicts incident HF in healthy individuals. Recently, another study has added to existing evidence linking low BMD with a higher rate of incident HF specifically for white men, while calling into question a similar association for white women. Additionally, decreased BMD was independently associated with left ventricular (LV) diastolic dysfunction. The mechanisms between reduced BMD and LV diastolic dysfunction remain unclear. One potential reason is that calcification of the arterial tissue resembles the process of osteogenesis, leading to impaired ventricle–vessel coupling due to arterial stiffness. Increased arterial stiffness raises LV afterload by elevating systolic blood pressure. Several reports support the hypothesis of an interplay between reduced BMD, elevated arterial stiffness, and LV diastolic dysfunction.

Heart failure and the risk of osteoporosis and osteoporotic fractures

There is an increasing interest in osteoporosis and reduced BMD affecting not only post-menopausal women but also men, particularly those with coexisting chronic diseases. Bone status in patients with stable chronic HF has been rarely studied so far (Table 1). In total, available data suggest that stable pre-transplant chronic HF patients have a significant but only moderately disturbed bone metabolism compared with cachectic HF patients or those who are candidates for heart transplantation. HF and osteoporosis are highly prevalent aging-related syndromes that exact an enormous impact on society. Both disorders are common causes of loss of function and independence, and of prolonged hospitalizations, presenting a heavy burden to the health care system. It remains an unanswered question whether HF leads to osteoporosis and frailty fractures, or if it is just an epiphenomenon as a passive participant in a population at risk for both syndromes. We have previously shown that bone mineral content (BMC) and BMD were reduced in non-cachectic men with HF, unlike to total lean and fat mass. Jankowska et al. confirmed reduced BMD and BMC in men with HF, which were predicted by HF severity and anabolic depletion. Although it can be expected that during HF progression changes in different tissue compartments are related, Jankowska et al. did not observe such relationships between longitudinal changes in bone, lean, and fat tissue mass in 60 men with HF who were followed up for between 2 and 4 years. A reduction in bone mass was accompanied by an increase in fat mass (arms, legs, and total body), while no changes were found in lean mass (arms, legs, and total body). The authors hypothesized that bone tissue was the body compartment where wasting due to anabolic depletion occurs first, which is in line with the assumption that fat is usually lost later in the catabolic process of HF than muscle. Reduced BMD with subsequently increased susceptibility to fractures has been noted in patients after heart transplantation, but in this group, increased bone loss is primarily mediated by high doses of glucocorticoids and cyclosporin therapy.

Impaired prognosis of patients with both heart failure and osteoporosis

Osteoporosis may have substantial prognostic significance in HF. Among patients with HF, lower BMD was associated with increased rates of death, implantation of an LV assist device, and/or inotrope dependency. When HF and osteoporosis are both present in a patient, subsequent mortality is more than additive. In men and women with HF, those with
Table 1  Systematic review of studies on bone status in heart failure

| Author         | Journal Year | No. of subjects | Study population | Main findings | Bone markers | Other |
|----------------|--------------|-----------------|------------------|---------------|--------------|-------|
| Bozic et al.   | J Card Fail 2009 | 93 (73 with HF) | Men stable EF <40% | ↓ BMD in HF vs. controls | ↑β-CTx, OC, OPG, RANKL in HF | — |
| Jankowska et al. | Eur J Heart Fail 2012 | 208 (187 with HF) | Men, mean age 60 | ↓ BMD in HF vs. non-HF | β-CTx, OC were not predictors of bone loss | Significant bone loss in 35% of pts with HF was determined by ↑NYHA and ↓testosterone |
| Kenny et al. | Osteoporos Int 2006 | 83 (60 with HF) | 43 HF men, mean age 77 + 17 HF women, mean age 78 | ↓ BMD in HF vs. controls | — | — |
| Terrovitis et al. | Eur J Heart Fail 2012 | 73 (60 with HF) | Men, mean age 57 | ↓ BMD in HF vs. non-HF | — | ↓BMD associated with impaired prognosis |
| Majumdar et al. | J Clin Endocrinol Metab 2012 | 49 509 (1841 with HF) | Subjects >50 years old | ↓ BMD in NYHA III/IV vs. I/II | — | 30% increased risk of osteoporotic fractures in HF |
| Wu et al. | Eur J Heart Fail 2012 | 102 (88 with HF) | 34 pts with VAD implantation | — | ↑β-CTx and NTX, =OC, P1NP in HF | VAD implantation: ↑P1NP, ↑β-CTx, and NTX |
| Zotos et al. | J Osteopor Phys Act 2014 | 73 (60 with HF) | Men, mean age 56 EF <40% | ↑β-CTx in HF | — | — |
| Schleithoff et al. | J Bone Min Metab 2003 | 42 (21 with HF) | Men, mean age 66 EF 29% | ↓ Hip BMD in NYHA III vs. NYHA II | ↓OC =β-CTx, NTx | No biochemical signs of enhanced bone resorption in HF men |
| Chen et al. | PloS ONE 2012 | 115 | Pts with stable HF (EF <45%), mean age 59 | ↑OPG in NYHA III vs. NYHA II | ↑OPG associated with ↑lip BMD |
| Youn et al. | Osteoporos Int 2015 | 65 with ADHF | 50 men, mean age 60 15 women, mean age 69 | 40% osteoporosis and 53% vertebral fracture in women 12% osteoporosis, 32% osteopenia, 12% vertebral fractures in men | — | Exercise capacity predictor of bone mass |

ADHF, acute decompensated heart failure; BMD, bone mineral density; β-CTx, β-CrossLaps; EF, ejection fraction; HF, heart failure; NTX, N-telopeptides of type I collagen; NYHA, New York Heart Association; OC, osteocalcin; OPG, osteoprotegerin; P1NP, procollagen-1 N-terminal peptide; Pts, patients; RANKL, receptor activator of nuclear factor-κB ligand; VAD, ventricular assist device.
both HF and hip fractures have a two-fold increased mortality relative to persons with HF without hip fractures.\textsuperscript{40} HF is also a major risk factor for mortality following hip fracture.\textsuperscript{41,42}

**Hip fracture as a fatal complication of osteoporosis in heart failure**

The importance of low BMD and deteriorated bone metabolism in patients with HF is in the increasing risk of fractures. This is compounded with poor physical performance, which will increase the risk of falls. In general, HF is associated with a four-fold higher risk of sustaining any fracture requiring hospitalization compared with patients with other cardiovascular diagnoses.\textsuperscript{43} In addition, the fracture incidence was 6% within 12 months among stable and non-cachectic HF patients.\textsuperscript{44} The most devastating complication of osteoporosis is hip fracture, which is associated with a high mortality risk and among those who survive, can lead to a loss of function and independence often necessitating admission to long-term care.\textsuperscript{45} In the Cardiovascular Health Study, a trend for a relationship between incident HF and incident hip fractures was reported.\textsuperscript{40} Similarly, in the Rochester Epidemiology Project, both prevalent and incident osteoporotic fractures were more common in HF patients compared with age-matched and sex-matched community controls, and this increased risk was almost entirely attributable to hip fractures.\textsuperscript{46} Osteoporotic fracture sites other than the hip have also been related with HF.\textsuperscript{47} In one study, approximately one-tenth of patients with HF were found to have vertebral compression fractures on radiographs, one half of these had multiple fractures, while the majority (85%) was not on treatment for osteoporosis.\textsuperscript{47} In a population-based study in Manitoba, Canada, including over 45,500 adults with 2703 incident osteoporotic fractures, which linked BMD data from 1998 to 2009 in those aged over 50 years with administrative databases, there was a 30% increase in major fractures in persons with HF.\textsuperscript{48} Instead of measuring bone mass directly, the assessment of bone metabolism, which reflects ongoing bone remodelling, may be an alternative for identifying HF patients at risk of osteoporosis and taking preventive and therapeutic measures in time.

**Bone metabolism in heart failure measured by bone markers**

Bone markers reflect early changes in bone metabolism and can thus provide insights in the physiology and pathophysiology of bone. Serum or urine levels outside of the normal range may be indicative for disturbances in bone turnover. Moreover, the assessment of bone turnover may reflect ongoing bone remodelling more accurately than bone mass measurements. They may be helpful in the prediction of future bone loss.\textsuperscript{35} Previous studies have reported conflicting results on collagen markers of bone metabolism in HF patients.\textsuperscript{49}

**Standard markers of bone metabolism in heart failure**

In adults, bone is constantly being remodelled, first being broken down (bone resorption) and then being rebuilt (bone formation). The resorption and reformation of bone are important for repair of microfractures and to allow modification of structure in response to stress and other biomechanical forces. Bone formation is normally tightly coupled to bone resorption, so that bone mass does not change. Bone diseases occur when formation and resorption are uncoupled. Several markers are available that measure bone turnover. These markers include collagen breakdown products and other molecules released from osteoclasts and osteoblasts during the process of bone resorption and formation. Osteocalcin and N-terminal propeptide of type I procollagen (PINP) are markers specific to bone formation, while markers specific to bone resorption include β-crossLaps (β-CTx). We have previously described increased serum levels of osteocalcin and β-CTx in HF patients indicating high bone turnover.\textsuperscript{52} Another study showed a strong elevation of bone resorption markers in HF patients that correlated negatively with LV ejection fraction.\textsuperscript{44} Zotos et al. have shown that β-CTx is correlated with the severity of HF and with the decrease in BMD.\textsuperscript{50} These bone markers, which accurately reflect early changes in bone metabolism, can be used to predict future bone loss. In addition, the osteoclastic marker β-CTx was strongly correlated with high morbidity and mortality in HF patients. To the best of our knowledge, it is the first marker of bone metabolism identified as a prognostic factor in chronic HF. Serum β-CTx can be easily measured and may be an interesting addition to an overall assessment of chronic HF, as a prognostic tool and for the early identification of patients at risk of osteoporosis. However, another study reported no significant differences in bone resorption (measured by β-CTx levels) in advanced HF.\textsuperscript{51} Less is known regarding bone formation markers and metabolism in patients with HF. However, Wu et al. did not find lower PINP levels in patients with advanced HF.\textsuperscript{49} PINP reflects an early phase of bone formation, namely, synthesis of procollagen type I. Later stages of bone formation that reflect mineralization of previously synthesized type 1 collagen are reflected by osteocalcin. Wu et al. did not find differences in osteocalcin in advanced HF patients. Similarly, Jankowska et al. showed that none of the investigated bone metabolism markers (osteocalcin and β-CTx) predicted bone loss during follow-up in men with chronic HF.\textsuperscript{33} Some discrepancies in the available studies may be explained by differences in populations under study.

\textit{Journal of Cachexia, Sarcopenia and Muscle} 2020; 11: 381–393

DOI: 10.1002/jcms.12516
**The role of receptor activator of nuclear factor-κB ligand and osteoprotegerin in bone metabolism in patients with heart failure**

The threshold level for bone loss or bone formation can be influenced by various local and systemic factors, which are known to modulate the bone remodelling process. Nuclear factor-κB is an important transcription factor in many cell types whose activation usually yields catabolic signalling. Several local factors such as receptor activator of nuclear factor-κB ligand (RANKL) and osteoprotegerin (OPG) originate from osteoblasts/stromal cells (Figure 1). They play a pivotal role in the control of osteoclastogenesis. RANKL is a key link between reduced oestrogen levels and osteoclast-mediated bone loss in post-menopausal women.\(^\text{52}–\text{54}\) Briefly, RANKL is involved in the differentiation and activation of osteoclasts, while OPG is associated with osteoclasts inhibition and apoptosis.\(^\text{55}\) Data from transgenic animals have shown that overexpression of RANKL can result in osteoporosis. OPG administration is able to reduce bone resorption processes in post-menopausal women.\(^\text{55}\) By binding RANKL and acting as a decoy receptor to competitively inhibit RANKL interaction with its receptor, OPG subsequently inhibits the production and differentiation of osteoclasts. As a result, bone resorption is inhibited.\(^\text{56}\) We have previously demonstrated an elevated OPG in chronic HF patients.\(^\text{32,57}\) The cause of high OPG in HF may be deduced through similar observation in natriuretic peptides in HF. In the GISSI-HF trial, OPG did also carry a prognostic function in patients with chronic HF.\(^\text{58}\) Chen et al. have noted an inverse relationship between OPG and BMD in HF patients.\(^\text{59}\) They suggested that OPG may be used as an indicator of osteopenia or osteoporosis clinically. However, the mechanism underlying OPG and BMD interaction in HF warrants further randomized prospective, outcome studies in larger population as well as basic research efforts.

**Figure 1** RANKL/osteoprotegerin interaction at the level of the bone. The essential signalling pathway for normal osteoclastogenesis. Under physiologic conditions, RANKL produced by osteoblasts binds to RANK on the surface of osteoclast precursors, triggering the transcription of osteoclastogenic genes. OPG inhibits the initiation of the process by binding to RANKL. OPG, osteoprotegerin; RANKL, receptor activator of nuclear factor-κB ligand.
Pathophysiology of reduced bone mass in heart failure

The pathophysiology of reduced bone mass in HF is not well understood. Aging is the most prominent confounder in the development of both bone loss and HF. Aging is a complex process that ultimately leads to morbidity including cardiovascular diseases and changes in body composition. The prevalence of HF rises to ≥10% among people over 70 years of age. Similarly, with aging, many changes in body composition occur including decrease of lean mass and BMD. As a result of aging of the human population worldwide, both HF and osteoporosis represent increasing burden for health care systems. With the aging of the human population, there is increasing risk of the diseases of the elderly including dementia. The burden of mortality from HF with dementia in the USA has been recently pointed out in the elderly population. On the other hand, the presence of dementia increased importantly the mortality risk after hip fracture surgery. More than one-third of people with dementia will die after hip fracture surgery in a 1 year follow-up and about one in two in more than 1 year follow-up. Patients with dementia usually have less activity and poor self-care ability leading to bone loss. Thus, the presence of dementia should be considered as the risk factor for bone loss, falls, and hip fracture in elderly patients with HF. Many non-endocrine and endocrine factors, which are firmly interrelated, may contribute to bone loss in HF (Figure 2). In addition to decreased physical performance in HF and sharing a number of common risk factors such as renal insufficiency, smoking, and diabetes, accelerated bone loss may also come from vitamin D deficiency and hyperparathyroidism, elevated aldosterone levels, and loop diuretic use in subjects with HF. Reduced mobility and muscle wasting

Patients with advanced HF have reduced mobility and decreased outdoor physical activity, which could influence vitamin D levels and bone metabolism. Exercise capacity independently predicts lumbar BMD, hip BMD, and femoral cortical thickness even after the adjustment for confounding variables. Muscle forces cause the largest burden on bones and the largest bone strains. Skeletal unloading due to prolonged bed rest or poor exercise capacity in HF patients leads to bone loss via reductions in the mechanical forces applied to bones. The mechanism of this bone loss appears to be a consequence of a decrease in the bone formation rate and a concurrent increase in the bone resorption rate. Skeletal muscle mass is an important predictor of exercise capacity, and it is an independent prognostic indicator of survival in patients with HF.

Figure 2 Factors contributing to bone loss in heart failure. CRP, C-reactive protein; IL-6, interleukin-6; RAAS, renin-angiotensin-aldosterone system; TNF, tumour necrosis factor.
HF patients. Some degree of muscle wasting is common even in mild HF. According to the muscle hypothesis, changes in the skeletal musculature are at the core of the deterioration of patients with HF. A loss of leg muscle mass seems to be an early event in the natural course of non-cachectic chronic HF.

Low vitamin D and secondary hyperparathyroidism

In HF, the increased losses of urinary calcium, due to long-term use of diuretics, the impaired absorption of these minerals and of vitamin D due to intestinal congestion, the decreased synthesis of 1,25-dihydroxyvitamin D secondary to liver congestion, renal insufficiency, and limited sunlight exposure, and finally, the high aldosterone levels are all causes of secondary hyperparathyroidism. The presence of vitamin D deficiency in HF population was more prominent than in healthy groups, that is, 90% of HF patients were vitamin D deficient, even in sunny climates. Secondary hyperparathyroidism was highly prevalent in elderly men with HF and was associated with impaired long-term survival. Additionally, HF patients with secondary hyperparathyroidism had more severe disease compared with those patients with normal serum parathyroid hormone (PTH) levels. Increased levels of PTH in patients with HF potentiate bone resorption and thus bone loss. Terrovitis et al. have shown that hyperparathyroidism was correlated with both severity of HF and decreased bone density, suggesting that increased PTH levels in HF might be an element of the underlying pathophysiological pathway leading patients to osteopenia or osteoporosis.

The role of the neurohumoral activation

There is a critical role for the renin–angiotensin–aldosterone system in both HF and osteoporosis. The angiotensin II receptor is a cell surface G-protein coupled receptor, which upon activation leads to intracellular increases in cyclic AMP. Activation of cyclic AMP signalling pathway can up-regulate receptor activator of RANKL expression in osteoblasts and subsequently activate osteoclasts responsible for bone resorption. In addition, angiotensin II regulates blood flow in both bone capillary and blood vessels’ endothelium, providing a functional link between osteoporosis and atherosclerosis. In addition, neurohormonal activation, manifested by elevated aldosterone levels, has been demonstrated to play a crucial role in the risk of orthopaedic fracture in animal models. Furthermore, the use of spironolactone is inversely associated with fractures in men with HF, suggesting that aldosterone may be important in fracture risk. Enhanced sympathetic outflow is one of the most important detrimental neurohormonal activation in HF. The importance of this model became even clearer when it was discovered that blockade of this sympathetic overactivity by beta-blockers prolongs survival in patients with HF. In animal studies, activation of the sympathetic nervous system led to the activation of β-adrenergic receptors on bone-forming osteoblasts, resulting in bone loss. Khosla et al. evaluated the role of sympathetic outflow and presented evidence to support the idea that the sympathetic nervous system regulates bone metabolism in humans, primarily via the β1-adrenergic receptor. Overall, growing clinical evidence suggests that pharmacological β1-adrenergic receptor-selective blockade may deliver a small but significant increase in bone mass and thus aid in the prevention of fractures. The use of beta-blockers is recommended standard treatment in patients with HF. However, we have found neither the study on the effect of the enhanced sympathetic outflow on bone status nor the evaluation of potentially beneficial effect of β-blockade on bone in the context of HF. Additionally, the significantly increased levels of cortisol in HF contribute to the predominance of catabolic factors. Reduced circulating levels of anabolic hormones and/or increased concentrations of catabolic hormones are correlated to reduced muscle mass, fat tissue, and bone mass. Excess of glucocorticoids (cortisol) directly inhibits bone forming cells and thus may contribute to the development of osteoporosis.

Adiponectin as a link between heart failure and bone loss

Adiponectin, an adipokine secreted by adipocytes, also plays a role in both cardiovascular disease and osteoporosis. Elevated adiponectin levels in HF reflect an attempt by the body to compensate for the impaired metabolism in this disease. Relative to osteoporosis, adiponectin stimulates osteoblast proliferation and differentiation. Previous meta-analysis including 51 studies found that adiponectin is the most relevant adipokine negatively associated with BMD independent of gender and menopausal status. In line with this finding, we have previously demonstrated that increased serum adiponectin levels were independent predictor of reduced BMD in elderly men with mild to moderate HF and showed a positive correlation to bone-specific surrogates. Furthermore, higher adiponectin levels are associated with increased fracture risk independent of body composition and BMD.

Hypogonadism

In elderly men, in particular, in men with HF, hypogonadism is a prevalent condition. Hypogonadism is a risk factor for osteoporosis, and testosterone replacement can increase BMD.
predicted by depleted gonadal and adrenal drive (as evidenced by low serum levels of testosterone and dehydroepiandrosterone sulphate) and thus contribute to general body wasting. However, we did not find an association between total testosterone and estimated free testosterone neither with bone status nor with lean mass and muscle strength. Literature data on androgen status in men with HF, assessed on the basis of serum levels of testosterone, are equivocal. In an unselected cohort of men with HF, Jankowska et al. have shown decreased serum levels of androgen hormones (testosterone and estimated free testosterone), which were markers of poor survival. In line with the results of Anker et al., we have found no difference in serum levels of testosterone between elderly men with HF and healthy controls. Additionally, androgen status was not predictive of long-term survival in our cohort of HF patients without diabetes. Difference in patients populations may be explanation of discrepancy between study results. Unlike to our study, Jankowska et al. included younger patients with more impaired renal function, while almost one-third of study patients were diabetics. In general, diabetes may be considered as the most prominent potential confounding variable that can lead to this discrepancy between studies.

Oxidative stress and inflammatory cytokines

Oxidative stress is at least partly responsible for the development and progression of HF. Reactive oxygen species directly impair contractile function by modifying proteins central to excitation contraction coupling, activate hypertrophy signalling kinases and transcription factors and mediate apoptosis, stimulate fibroblast proliferation, and activate matrix metalloproteinase. An imbalance between oxidant and antioxidant statuses is associated with increased osteoclastic and decreased osteoblastic activity. Inflammatory cytokines may also alter the bone metabolism. Tumour necrosis factor and interleukin-6 are increased in chronic HF, and inflammation might play an important role in its development and progression (‘cytokine hypothesis’). Interleukin-6 levels are increased in HF patients and correlated with markers of bone turnover. Therefore, in this inflammatory state, the resorption of bone may be promoted by pro-osteoclastogenic cytokines.

Reduced tissue perfusion

Factors related to HF may play a role in reduced bone mass. For example, reduced tissue perfusion in patients with HF might block the proliferation and differentiation of osteoblasts, while strongly stimulating osteoclasts. However, the resorptive function of osteoclasts is not disturbed under hypoxic conditions. The negative impact of HF on bone metabolism might be associated with the direct impact of reduced pO2 and pH. Studies evaluating anti-osteoporotic drugs exclusively in HF patients are missing.

Drugs

A number of drugs used to treat HF can impact the risk of developing osteoporosis. Loop diuretic use has been associated with increased loss in BMD at the hip in men, and prolonged use of loop diuretics has been directly associated with total fractures in post-menopausal women, but not with hip or clinical vertebral fractures. Vitamin K is required for the carboxylation of osteocalcin, and it has been shown that individuals supplemented with vitamin K had increased serum levels of carboxylated osteocalcin and decreased undercarboxylated osteocalcin. Therefore, vitamin K antagonists may have influenced the measurements of osteocalcin. Epidemiological studies show that this abnormal vitamin K metabolism may increase osteoporotic fracture risk.

Initiation of antihypertensive drugs, including some standard drugs for the treatment of HF (angiotensin-converting enzyme inhibitor, angiotensin II receptor blocker, or beta-adrenergic blocker), is a risk factor for falls in the elderly. Current ESC guidelines on HF suggest that drug therapy in older patients should follow the recommendations but with special attention due to the frailty, co-morbidities, cognitive impairment, and limited social support of this population. Thus, one of the recommendations is to optimize doses of HF medication slowly and with frequent monitoring of clinical status and to reduce polypharmacy (number, doses, and complexity of regime) in order to avoid side effects of drugs including orthostatic hypotension that predisposes to the falls and fractures in those patients.

Treatment of bone loss in heart failure

The development of preventive and therapeutic strategies against bone loss, sarcopenia, and wasting disorders is perceived as an urgent need by health care professionals. However, the treatment of bone loss and wasting leading to cachexia is an unresolved challenge to this day. As wasting is a multifactorial disorder, it is unlikely that any single agent will be completely effective in treating this condition; thus, it will be necessary to target different pathways. Additional research is warranted for further evaluation of the molecular pathways linking osteoporosis and HF, which could identify novel therapeutic targets for prevention of both conditions. Studies evaluating anti-osteoporotic drugs exclusively in HF patients are missing.

Exercise

Exercise appears to increase BMD. Greater physical activity is associated with a 9–17% increase in BMD during adolescence and young adulthood. Being a part of daily living, exercise...
is the easiest way to preserve and increase muscle mass; also, it is the most effective anabolic agent with many ancillary effects delivered at no or low costs. Muscle wasting might be present even in younger patients with HF, particularly in those who are in poor clinical condition. Exercise restores muscle stem cell mobilization, regenerative capacity, and muscle metabolic alterations via adiponectin/AdipoR1 activation in mice. Among all investigated therapeutic strategies, aerobic exercise training in HF patients is the best proven to counteract skeletal muscle wasting and is recommended by treatment guidelines for HF. Preservation of muscle mass and muscle strength is of crucial importance for bone health. Oscillatory whole-body vibration is a novel exercise modality, which is performed on a vibrating platform that moves in sinusoidal oscillations and during which static and dynamic exercises can be performed. Whole-body vibration therapy can provide a significant improvement in reducing bone loss and reduce risk of falls in post-menopausal women. Furthermore, its application improved exercise capacity, lower limb performance, and quality of life in patients with chronic diseases such as chronic obstructive pulmonary disease and pulmonary arterial hypertension. Thus, it would be of interest to assess the role of whole-body vibration on body compartments as a feasible and easily accessible method of continuous and potentially home-based physical exercise in patients with HF.

**Drugs and devices**

At least 19 drugs that can regulate muscle mass have been reported in the literature so far. These therapeutic interventions include use of anti-inflammatory substances and appetite stimulants. It has been demonstrated that testosterone therapy reveals favourable effects in men with HF (e.g. improvement in exercise capacity, amelioration of neurohumoral activation, improvement in insulin sensitivity, and anti-inflammatory effects). Direct anabolic properties of testosterone or indirect effects of this therapy may also potentially improve bone homeostasis in HF patients. Moreover, favourable effects of testosterone on bone mass have not been confirmed in all published studies. Recently, a study revealed that alendronate, one of bisphosphonates, may reduce the risk of HF compared with control subjects. However, other bisphosphonate users were at increased risk of HF. Therefore, further research on bisphosphonate and HF is warranted. To our knowledge, the efficacy/safety analysis of bisphosphonates in exclusively HF patients with osteoporosis has not been previously performed. Statins are drugs with seemingly multiple actions, for which a possible effect on bone mass has been suggested. However, such an effect is still discussed, and conflicting results have been published in this regard in the general population. No data on the effectiveness of these drugs exist in terms of effects on bone status in HF patients. Despite the publication of studies exploring various doses and forms of vitamin D supplementation in patients with chronic HF, there remains considerable uncertainty regarding the benefits of this therapeutic approach. In the majority of these studies, there was no effect of vitamin D supplementation on HF symptoms except in the study by Boxer et al. who observed an improvement in quality of life in HF patients allocated to vitamin D supplementation. However, even the most recent study did not find improvements in physical performance (6 min walk distance) in patients with HF after vitamin D supplementation, albeit beneficial effects on LV structure and function were noted. The single study that evaluated vitamin D supplementation on bone metabolism in patients with HF showed no influence on bone turnover markers. Wu et al. showed that the haemodynamic improvement and mechanical unloading after ventricular assist device implantation are associated with a trend towards lower serum PTH levels and lower bone resorption markers and significantly higher bone formation markers in HF patients. Improved renal function with increased estimated glomerular filtration rate would be expected to decrease PTH levels, therefore reducing the degree of secondary hyperparathyroidism.

**Gaps in evidence and future perspective**

1. Major HF guidelines do not cover the screening method or patient education in terms of osteoporosis or osteoporotic fracture, even though HF represents a substantially increased risk of fracture. Future HF guidelines should consider this issue.

2. New data are required to prove that testosterone deficiency may be the mechanistic explanation for bone loss in men with HF. A desirable methodological approach here would be an assessment of whether correction of testosterone deficiency could improve bone mass in these patients.

3. Further research is needed to confirm the potential of adiponectin and other adipokines in the crosstalk between musculoskeletal system and energy metabolism in HF. Interventional studies using the application of adiponectin or its mimicking agent osmotin may provide new insight into whether there is a causal relationship between adiponectin and musculoskeletal depletion.

4. It would be interesting to assess the potential biochemical crosstalk between skeletal muscle and bone metabolism, via biohumoral markers produced by muscles called myokines, in both healthy subjects and patients with HF. The role of myokines may be of importance for beneficial influence of physical training in healthy subjects.
However, there are no data evaluating if beneficial effect of physical training may be regulated by myokines in patients with HF.

5. The mechanism underlies OPG/RANKL, and bone status in HF warrants further randomized prospective, outcome study in larger population and bench works.

6. Secondary hyperparathyroidism is a potential cause for bone loss in the context of HF, which may be treated with cinacalcet. No study to date has evaluated the prognostic effect of adjustment of serum PTH by cinacalcet in HF patients. Cinacalcet prevents hyperparathyroidism and its consequences. Treatment with the drug significantly lowers the rates of cardiovascular death and major cardiovascular events in patients on haemodialysis. If future studies prove the beneficial prognostic effect of PTH adjustment, PTH may transform from risk marker to modifiable risk factor in the context of HF with establishment of new treatment target in this severe disease.

7. It would be of interest to assess efficacy/safety profile of anti-osteoporotic drugs in the context of HF including bisphosphonates, vitamin D supplementation, selective oestrogen receptor modulator (raloxifene), and biologicals (denosumab).

## Conclusions

Heart failure and osteoporosis are highly prevalent aging-related diseases that exact a huge impact on society. Published studies show that HF is related with reduced BMD and increased risk of osteoporotic fractures, especially in those with more severe HF. Both disorders are common causes of loss of function and independence, and of prolonged hospitalizations, presenting a heavy burden on the health care system. When HF and osteoporosis are both present in a patient, subsequent mortality is more than additive. On the other hand, current HF guidelines do not suggest screening methods or patient education for osteoporosis or osteoporotic fractures. Thus, this review and as well as other studies may serve as a base to discuss the necessities of bone health evaluation in HF patients.

## Acknowledgements

The authors of this manuscript certify that they comply with the ethical guidelines for authorship and publishing in the *Journal of Cachexia, Sarcopenia and Muscle*. The authors acknowledge the project (Burden of cachexia and sarcopenia in patients with chronic diseases: epidemiology, pathophysiology and outcomes; ID J3-9292) and project (Epidemiology, patophysiology and clinical significance of iron deficiency in chronic cardiopulmonary disease; ID J3-9284) was financially supported by the Slovenian Research Agency.

## Funding

This work was supported by the European Commission’s 7th Framework Programme (FP7, grant number 241558).

## Conflict of interest

Goran Loncar, Natasa Cvetinovic, Mitja Lainscak, Andjelka Isakovic, and Stephan von Haehling declare that they have no conflict of interest. All authors declare that the submitted work has not been published before.

## References

1. Mosterd A, Hoes AW. Clinical epidemiology of heart failure. *Heart* 2007;93:1137–1146.
2. Crespo-Leiro MG, Anker SD, Maggioni AP, Coats AJ, Filippatos G, Ruschitzka F, et al. European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions. *Eur J Heart Fail* 2016;18:613–625.
3. Omera D, Farkas I, Erzen I, Lainscak M. National trends in heart failure hospitalization rates in Slovenia 2004-2012. *Eur J Heart Fail* 2016;18:1321–1328.
4. Gabet A, Juillière Y, Lamarche-Vadel A, Vernay M, Olé V. National trends in rate of patients hospitalized for heart failure and heart failure mortality in France, 2000-2012. *Eur J Heart Fail* 2015;17:583–590.
5. Christ M, Stöhr S, Därr M, Heppner HJ, Müller C, Wachter R, et al. Heart failure epidemiology 2000-2013: insights from the German Federal Health Monitoring System. *Eur J Heart Fail* 2016;18:1009–1018.
6. Fülster S, Tacke M, Sandek A, Ebner N, Tschöpe C, Doehner W, et al. Muscle wasting in patients with chronic heart failure: results from the studies investigating co-morbidities aggravating heart failure (SICA-HF). *Eur Heart J* 2013;34:512–519.
7. Hajahmadi M, Shemshadi S, Khalilipour E, Amin A, Taghavi S, Maleki M, et al. Muscle wasting in young patients with dilated cardiomyopathy. *J Cachexia Sarcopenia Muscle* 2017;8:542–548.
8. Zengin A, Jarjou LM, Prentice A, Cooper C, Ebeling PR, Ward KA. The prevalence of sarcopenia and relationships between muscle and bone in ageing West-African Gambian men and women. *J Cachexia Sarcopenia Muscle* 2018;9:920–928.
9. Katz AM, Katz PB. Diseases of the heart in the works of Hippocrates. *Br Heart J* 1962;24:257–264.
10. Loncar G, Springer J, Anker MS, Doehner W, Lainscak M. Cardiac cachexia: hic et nunc. *J Cachexia Sarcopenia Muscle* 2016;7:246–260.
11. von Haehling S, Anker SD. Prevalence, incidence and clinical impact of cachexia: facts and numbers—update 2014. *J Cachexia Sarcopenia Muscle* 2014;5:261–263.
12. Pocock SJ, McMurray JJ, Dobson J, Yusuf S, Granger CB, Michelson EL, et al. Weight loss and mortality risk in patients with chronic heart failure in the candesartan in patients with chronic heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. Eur Heart J 2008:29:2641–2650.

13. Anker SD, Ponikowski P, Varney S, Chua TP, Clark AL, Webb-Peploe KM, et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet 1997;349:1050–1053.

14. von Haehling S, Lainscak M, Springer J, Anker SD. Cardiac cachexia: a systematic overview. Pharmacol Ther 2009;121:227–252.

15. Emami A, Saitoh M, Valentova M, Sandek A, Evertz R, Ebner N, et al. Comparison of sarcopenia and cachexia in men with chronic heart failure: results from the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF). Eur J Heart Fail 2018;20:1580–1587.

16. Anker SD, Chua TP, Ponikowski P, Harrington D, Swan JW, Kox WJ, et al. Hormonal changes and catabolic/anabolic imbalance in critical illness and heart failure and their importance for cardiac cachexia. Circulation 1997;96:526–534.

17. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Eur J Heart Fail 2016;18:891–975.

18. Zio A, Magalhaes S, Santos M. Frailty in cardiovascular disease: screening tools. Rev Port Cardiol 2019;38:143–158.

19. Uchmanowicz I, Mlynarska A, Lisiak M, Kulażna-Oleský M, Wleklik M, Chudiak A, et al. Heart failure and problems with frailty syndrome: why it is time to care about frailty syndrome in heart failure. Card Fail Rev 2019;5:4–37.

20. Marchowitz PA, Tora VH, Franklin BA, O’Neill WW, Jerkys M, Boura J, et al. Usefulness of bone mineral density to predict significant coronary artery disease. Am J Cardiol 2005;96:1059–1063.

21. von der Recke P, Hansen MA, Hassager C. The association between low bone mass at the menopause and cardiovascular mortality. Am J Med 1999;106:273–278.

22. Sprini D, Rini GB, Di Stefano L, Gianferrito L, Napoli N. Correlation between osteoporosis and cardiovascular disease. Clin Cases Miner Bone Metab 2014;11:17–119.

23. Pfister R, Michels G, Sharp SJ, Luben R, Wareham NJ, Khaw KT. Low bone mineral density predicts incident heart failure in men and women: the EPIC (European Prospective Investigation into Cancer and Nutrition)-Norfolk prospective study. JACC Heart Fail 2014;2:380–389.

24. Fothung RB, Brown DL, Koh WJ, Bartz TM, Carbone LD, Civitelli R, et al. Bone mineral density and risk of heart failure in older adults: the Cardiovascular Health Study. J Am Heart Assoc. 2017;6(3). pii: e004344.

25. Wang RT, Li XS, Zhang JR, Sun Y, Yu KJ, Liu T. Bone mineral density is associated with left ventricular diastolic function in women. Clin Cardiol 2016;39:709–714.

26. Wang RT, Liu HT, Zhao YL, Sun Y, Yu KJ, Liu T. Bone mineral density is associated with left ventricular diastolic function in men with type 2 diabetes. Diabetes Metab 2016;42:256–262.

27. Danilevicius CF, Lopes JB, Pereira RM. Bone metabolism and vascular calcification. Braz J Med Biol Res 2007;40:435–442.

28. Zito C, Mohammed M, Todorov MC, Khandheria BK, Cusmâ-Piccione M, Oreo G, et al. Interplay between arterial stiffness and diastolic function: a marker of ventricular-vascular coupling. J Cardiovasc Med (Hagerstown) 2014;15:788–796.

29. London GM, Guerin A. Influence of arterial pulse and reflective waves on systolic blood pressure and cardiac function. J Hypertens Suppl 1999;17:53–56.

30. Cecelja M, Chowienczyk P. Role of arterial stiffness in cardiovascular disease. JRSM Cardiovasc Dis. 2012;1(4). pii: cvd.2012.012016.

31. Lampropoulos CE, Papaioannou I, D’Cruz DP. Osteoporosis—a risk factor for cardiovascular disease? Nat Rev Rheumatol 2012;8:587–598.

32. Bozic B, Loncar G, Prodanovic N, Radiojic Z, Cvorovic V, Dimovic S, et al. Relationship between high circulating adiponectin with bone mineral density and bone metabolism in elderly males with chronic heart failure. J Card Fail 2010;16:301–307.

33. Jankowska EA, Jakubaszko J, Cwynar A, Majda J, Ponikowska B, Kustrzycka-Kratochwil D, et al. Bone mineral status and bone loss over time in men with chronic systolic heart failure and their clinical and hormonal determinants. Eur J Heart Fail 2009;11:28–38.

34. Kenny AM, Boxer R, Walsh S, Hager WD, Raisz LG. Femoral bone mineral density in patients with heart failure. Osteoporos Int 2006;17:1420–1427.

35. Zittermann A, Schleithoff SS, Koerfer R. Markers of bone metabolism in congestive heart failure. Clin Chim Acta 2006;366:27–36.

36. von Haehling S. The wasting continuum in heart failure: from sarcopenia to cachexia. Proc Nutr Soc 2015;74:367–377.

37. Glendening P, Kent GN, Adler BD, Matz L, Watson I, O’Driscoll GJ, et al. High prevalence of osteoporosis in cardiac transplant recipients and discordance between biochemical turnover markers and bone histomorphometry. Clin Endocrinol 1999;50:247–355.

38. Alouco AO, Jesse J, Habal H, Garcia-Rossel M, Shah R, Reed G, et al. Heart failure as a risk factor for osteoporosis and fractures. Curr Osteoporos Rep 2012;10:258–269.

39. Terwiss J, Zotos P, Kaldara D, Diakos N, Tseliou E, Vakrou S, et al. Bone mass loss in chronic heart failure is associated with secondary hyperparathyroidism and has prognostic significance. Eur J Heart Fail 2012;14:326–332.

40. Carbone I, Buzkova P, Fink HA, Lee JS, Chen Z, Ahmed A, et al. Hip fractures and heart failure: findings from the Cardiovascular Health Study. Eur Heart J 2010;31:77–84.

41. Cullen MW, Gullerud RE, Larson DR, Melton LJ 3rd, Huddleston JM. Impact of heart failure on hip fracture outcomes: a population-based study. J Hosp Med 2011;6:507–512.

42. Frost SA, Nguyen ND, Black DA, Eisman JA, Nguyen TV. Risk factors for in-hospital post-hip fracture mortality. Bone 2011;49:553–558.

43. van Diepen S, Majumdar SR, Bakal JA, McAlister FA, Ezekowitz JA. Heart failure is a risk factor for orthopedic fracture: a population-based analysis of 16,294 patients. Circulation 2008;118:1946–1952.

44. Frost RJ, Sonne C, Wehr U, Stempfle HU. Effects of calcium supplementation on bone loss and fractures in congestive heart failure. Eur J Endocrinol 2007;156:309–314.

45. Jiang HX, Majumdar SR, Dick DA, Moreau M, Rao S, Otto DD, et al. Development and initial validation of a risk score for predicting in-hospital and 1-year mortality in patients with hip fractures. J Bone Miner Res 2005;20:494–500.

46. Gerber Y, Melton LJ III, Weston SA, Roger VL. Osteoporotic fractures and heart failure in the community. Am J Med 2011;124:418–425.

47. Lyons KJ, Majumdar SR, Ezekowitz JA. The unrecognized burden of osteoporosis-related vertebral fractures in patients with heart failure. Circ Heart Fail 2011;4:419–424.

48. Majumdar SR, Ezekowitz JA, Liu LM, Leslie WD. Heart failure is a clinically and densitometrically independent risk factor for osteoporotic fractures: population-based cohort study of 45,509 subjects. J Clin Endocrinol Metab 2012;97:1179–1186.

49. Liu H, Lee SK, Pronschinsky K, Qiu S, Naka Y, Takayama H, et al. Dynamics of bone turnover markers in patients with heart failure and following haemodynamic improvement through ventricular assist device implantation. Eur J Heart Fail 2012;14:1356–1365.

50. Zotos P, Kalinka D, Kapelios C, Souvonis V, Nana E, Agapitou V, et al. Bone metabolism in chronic heart failure. J Osteopor Phys Act 2014;2:121.

51. Schleithoff SS, Zittermann A, Stuttgen B, Tenderich G, Berthold HK, Körfer R, et al. Low serum levels of intact osteocalcin in patients with congestive heart failure. J Bone Miner Metab 2003;21:247–252.

52. Boyce BF, Xing L. Biology of RANK, RANKL, and osteoprotegerin. Bone Miner Metab 2003;31:437–442.

53. Papageorgiou M, Sathiyapalan T, Schulte R. Muscle mass loss and incident osteoporosis in a large cohort of postmenopausal women. J Cachexia Sarcopenia Muscle 2019;10:131–139.

54. Yoo JJ, Kim MJ, Na JB, Chun YH, Park YJ, Park Y, et al. Relationship between...
endothelial function and skeletal muscle strength in community dwelling elderly women. J Cachexia Sarcopenia Muscle 2018;9:1034–1041.
55. Aubin JE, Bonnelye E. Osteoprotegerin and its ligand: a new paradigm for regulation of osteoclastogenesis and bone resorption. Osteoporos Int 2000;11:905–913.
56. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003;23:337–342.
57. Loncar G, Bozik B, Cvorovic V, Radojicic Z, Dinovik S, Markovic N, et al. A relationship between RANKL and neuroendocrine activation in elderly males with heart failure. Endocrine 2010;37:148–156.
58. Roysland R, Masson S, Omland T, Milani V, Bjerre M, Flyvbjerg A, et al. Prognostic value of osteoprotegerin in chronic heart failure: the GISSI-HF trial. Am Heart J 2010;160:286–293.
59. Chen YH, Wu YW, Yang WS, Wang SS, Lee CM, Chou NK, et al. Relationship between bone mineral density and serum osteoprotegerin in patients with chronic heart failure. PLoS ONE 2012;7:e44242.
60. Janssens MR, Inglis JE, Reilly W, Kelly OL, Ilijich Z. Aging human body: changes in bone, muscle and body fat with consequent changes in nutrient intake. J Endocrinol 2017;234:R35–R51.
61. Vuong JT, Jacob SA, Alexander KM, Singh A, Liao R, Desai AS, et al. Mortality from heart failure and dementia in the United States: CDC WONDER 1999-2016. J Card Fail 2019;25:125–129.
62. Bai J, Zhang P, Liang X, Wu Z, Wang J, Liang Y. Association between dementia and mortality in the elderly patients undergoing hip fracture surgery: a meta-analysis. J Orthop Surg Res 2018;13:298.
63. Shane E, Mancini D, Aaronson K, Silverberg SJ, Seibel MJ, Addesso V, et al. Bone mass, vitamin D deficiency, and hyperparathyroidism in congestive heart failure. Am J Med 1997;103:197–207.
64. Chhokar VS, Sun Y, Bhattacharya SK, Ahokas RA, Forsers LK, Xing Z, et al. Loss of bone minerals and strength in rats with aldosteronism. Am J Physiol Heart Circ Physiol 2004;287:H2023–H2026.
65. Lim LS, Fink HA, Kuskowski MA, Taylor BC, Schousboe JT, Ensrud KE, et al. Loop diuretic use and increased rates of hip bone loss in older men: the Osteoporotic Fractures in Men Study. Arch Intern Med 2008;168:735–740.
66. Youn JC, Lee SJ, Lee HS, Oh J, Hong N, Park S, et al. Exercise capacity independently predicts bone mineral density and proximal femoral geometry in patients with acute decompensated heart failure. Osteoporos Int 2015;26:2121–2129.
67. Zengin A, Pye SR, Cook MJ, Adams JE, Rawer R, Wu FCW, et al. Associations of muscle force, power, cross-sectional muscle area and bone geometry in older UK men. J Cachexia Sarcopenia Muscle 2017;8:598–606.
68. Bkle DD, Halloran BP. The response of bone to unloading. J Bone Miner Metab 1999;17:233–244.
69. Cicioara M, Zanolla L, Franceschini L, Rossi A, Golia G, Zamboni M, et al. Skeletal muscle mass independently predicts peak oxygen consumption and ventilatory response during exercise in noncafeine patients with chronic heart failure. J Am Coll Cardiol 2001;37:2080–2085.
70. Loncar G, Bozik B, von Haehling S, Duengh HD, Cvetinovic N, Prodanovic N, et al. Skeletal muscle status and its prognostic role in men with heart failure with reduced ejection fraction. Eur Heart J 2016;37:843.
71. Loncar G, Bozik B, von Haehling S, Duengh HD, Prodanovic N, Lainscak M, et al. Association of adiponectin with peripheral muscle status in elderly patients with heart failure. Eur J Intern Med 2013;24:818–823.
72. Coats AJ, Clark AL, Piepoli M, Verrelli M, Poole-Williams PA. Symptoms and quality of life in heart failure: the muscle hypothesis. Br Heart J 1994;72:536–539.
73. Anker SD, Ponikowski PP, Clark AL, Levy F, Rauchhaus M, Kemp M, et al. Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure. Eur Heart J 1999;20:683–693.
74. Hagstrom E, Ingelsson J, Sundstrom J, Hellman P, Larsson TE, Berglund L, et al. Plasma parathyroid hormone and risk of congestive heart failure in the commu- nity. Eur J Heart Fail 2010;12:1186–1192.
75. Schierbeck LL, Jensen TS, Bang U, Jensen G, Kaber L, Jensen JE. Parathyroid hormone and vitamin D markers for cardiovascular and all cause mortality in heart failure. Eur J Heart Fail 2011;13:626–632.
76. Loncar G, Bozik B, Cvetinovic N, Duengh HD, Lainscak M, von Haehling S, et al. Secondary hyperparathyroidism prevalence and prognostic role in elderly males with heart failure. J Endocrinol 2017;40:297–304.
77. Kim DH, Sabour S, Sagar UN, Adams S, Wheeldon AE. Omega-3 fatty acid-related hypervitaminosis D in cardiovascular disease (from the National Health and Nutrition Examination Survey 2001–2004). Am J Cardiol 2008;102:1540–1544.
78. Ameri P, Ronco D, Casu M. High prevalence of vitamin D deficiency and its association with left ventricular dilatation: an echocardiography study in elderly patients with chronic heart failure. Nutr Metab Cardiovasc Dis 2010;20:533–640.
79. Kamalov G, Ahokas RA, Zhao W, Zhao T, Shahbaz AU, Johnson PL, et al. Uncoupling the coupled calcium and zinc dyshomeostasis in cardiac myocytes and mitochondria seen in aldosteronism. J Cardiovasc Pharmacol 2010;55:248–254.
80. Nakagami H, Morishita R. Effect of angiotensin II on bone metabolism. Clin Calcium 2009;19:997–1002.
81. Guan XK, Zhao Y, Li Y. Reciprocal roles of AngII type I and AngII type 2 receptors blockade (ARB) in regulating Cbfa1/RANKL via cAMP signaling pathway: possible mechanism for hypertension-related osteoporosis and antagonistic effect of ARB on hypertension-related osteoporosis. Int J Mol Sci 2011;12:4206–4213.
82. Shimizu H, Nakagami H, Osako MK, Hanayama R, Kunugiza Y, Kizawa T, et al. Angiotensin II accelerates osteoporosis by activating osteoclasts. FASEB J 2008;22:2465–2475.
83. Carbone LD, Cross JD, Raza SH, Busch AJ, Sepanski RJ, Dhawan S, et al. Fracture risk in men with congestive heart failure risk reduction with spironolactone. J Am Coll Cardiol 2008;52:135–138.
84. Braunwald E. Normal and abnormal myocardial function. In Braunwald E et al., eds. Harrison’s Principles of Internal Medicine, 15th ed. New York: McGraw-Hill; 2001. p 1309–1318.
85. Takeda S, Elefteriou F, Velesarre V, Liu X, Zhao L, Parker KL, et al. Leptin regulates bone formation via the sympathetic nervous system. Cell 2002;111:305–317.
86. Khosla S, Drake MT, Volkman TL, Thrice BS, Achenbach SJ, Atkinson EJ, et al. Sym- pathetic α1-adrenergic signaling contributes to regulation of human bone metabolism. J Clin Invest 2018;128:4832–4842.
87. Hofbauer LC, Hennecie H. J-Blockers and bone health. J Clin Invest 2018;128:4745–4747.
88. O’Brien CA, Jia D, Plotkin LI, Bellido T, Powers CC, Stewart SA, et al. Glucocorticoids act directly on osteoblasts and osteocyttes to induce their apoptosis and reduce bone formation and strength. Endocrinology 2004;145:1835–1841.
89. Biolo A, Shibata R, Ouchi N, Kihara S, Sonoda M, Walsh K, et al. Determinants of adiponectin levels in patients with chronic systolic heart failure. Am J Cardiol 2010;105:1147–1152.
90. Barbour KE, Zmuda JM, Boudreau R, Strotmeyer ES, Horwitz MJ, Evans RW, et al. Adipokines and the risk of fracture in older adults. J Bone Miner Res 2011;26:1568–1575.
91. Luo X, Guo L, Yuan QX, Xie ZH, Hou HD, Wu XP, et al. Adiponectin stimulates human osteoblasts proliferation and differentiation via the MAPK signaling pathway. Exp Cell Res 2005;309:99–109.
92. Biver E, Salliot C, Combesure C, Gossec L, Harfoudin P, Legroux-Gerot I, et al. Influence of adiponectin and ghrelin on bone mineral density and fracture risk: a systematic review and meta-analysis. J Clin Endocrinol Metab 2011;96:2703–2713.
93. Naghi JJ, Philip KJ, Dilibero D, Willix R, Schwarz ER. Testosterone therapy: treat- ment of metabolic disturbances in heart failure. J Cardiovasc Pharmacol Therapeut 2011;16:14–23.
94. Wehr E, Pilz S, Boehm BO, Mérz W, Grammer T, Obermayer-Pietsch B. Low free testosterone is associated with heart failure mortality in older men referred for coronary angiography. Eur J Heart Fail 2011;13:482–488.
95. Zacharin MR, Pua J, Kanumakala S. Bone mineral density outcomes following long-term treatment with subcutaneous
Bone in heart failure

104. Deswal A, Petersen NJ, Feldman AL, Loncar G, Bozic B, Neskovic AN, Tsutsui H, Kinugawa S, Matsushima S. Oxidative stress and heart failure. *Circulation* 2017;135:1829–1837.

105. Takimoto E, Kass DA. Role of oxidative stress in cardiac hypertrophy and remodeling. *Hypertension* 2007;49:241–248.

106. Tsutsui H, Kinugawa S, Matsushima S. Oxidative stress and heart failure. *Am J Physiol Heart Circ Physiol* 2010;301:H2181–H2190.

107. Altingad O, Erel O, Soran N, Celik H, Selek O. Total oxidative/anti-oxidative status of the relationship of physical activity to bone mineral accrual from adolescence to young adulthood. *Bone* 2008;43:1101–1107.

108. Inoue A, Cheng XW, Huang Z, Hu L, Kikuchi R, Jiang H, et al. Exercise restores muscle stem cell mobilization, regenerative capacity and muscle metabolic alterations via adiponectin/AdipoR1 activation in SAMP10 mice. *J Cachexia Sarcopenia Muscle* 2018;9:465–481.

109. Baxter-Jones AD, Kontulainen SA, Faulkner RA, Bailey DA. A longitudinal study of the relationship of physical activity to bone mineral accrual from adolescence to young adulthood. *Bone* 2008;43:1101–1107.

110. Neskovic AN, Tsutsui H, Kinugawa S, Matsushima S. Total oxidative/anti-oxidative status. *Endocr Rev* 2011;32:465–481.

111. Inoue A, Cheng XW, Huang Z, Hu L, Kikuchi R, Jiang H, et al. Exercise restores muscle stem cell mobilization, regenerative capacity and muscle metabolic alterations via adiponectin/AdipoR1 activation in SAMP10 mice. *J Cachexia Sarcopenia Muscle* 2018;9:465–481.

112. Zittermann A, Ernst JB, Prokop S, Fuchs U, Dreier J, Kuhn J, et al. Vitamin D supplementation and bone turnover in advance heart failure: the EVITA trial. *Osteoporos Int* 2018;29:579–586.

113. Boxer RS, Hott BD, Schmotzer BJ, Stefano GT, Gomes A, Negrea L. The effect of vitamin D on aldosterone and health status in patients with heart failure. *J Card Fail* 2014;20:334–342.

114. Witte KK, Byrom R, Gierula J, Paton MF, Jamil HA, Lowry JE, et al. Effects of vitamin D on cardiac function in patients with chronic HF: the VINDICATE study. *J Am Coll Cardiol* 2016;67:2593–2603.

115. Pedersen BK, Febbraio MA. Muscle as an endocrine organ: focus on muscle derived interleukin-6. *Physiol Rev* 2008;88:1379–1406.

116. Selektor Y, Ahokas RA, Bhattacharya SK, Sun Y, Gerling IC, Weber KT. Cinacalcet and the prevention of secondary hyperparathyroidism in rats with aldosteronism. *Am J Med Sci* 2008;335:105–110.

117. Moe SM, Chertow GM, Parfrey PS, Kubo Y, Block GA, Correa-Rotter R, et al. Evaluation of cinacalcet HCl therapy to lower cardiovascular events (EVOLVE) trial investigators*. Cinacalcet, fibroblast growth factor-23, and cardiovascular disease in hemodialysis: the evaluation of cinacalcet HCl therapy to lower cardiovascular events (EVOLVE) trial. *Circulation* 2015;132:27–39.

118. von Haehling S, Morley JE, Coats AJS, Anker SD. Ethical guidelines for publishing in the Journal of Cachexia, Sarcopenia and Muscle: update 2017. *J Cachexia Sarcopenia Muscle* 2018;8:1081–1083.